Free Trial
→ A letter from Shannon Stansberry (From Porter & Company) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Can-Fite BioPharma Ltd. stock logo
CANF
Can-Fite BioPharma
$1.67
+3.0%		$2.16
$1.50
▼
$12.30
$1.79M1.16880,380 shs14,117 shs
CNS Pharmaceuticals, Inc. stock logo
CNSP
CNS Pharmaceuticals
$4.34
-4.6%		$5.24
$1.90
▼
$10.54
$6.65M3.2116,535 shs4,019 shs
Enveric Biosciences, Inc. stock logo
ENVB
Enveric Biosciences
$1.46
-2.7%		$1.46
$1.17
▼
$13.25
$6.71M1.2350,913 shs35,765 shs
Scienture Holdings, Inc. stock logo
SCNX
Scienture
$3.42
-0.9%		$5.88
$2.64
▼
$21.50
$6.09M3.5762,318 shs14,100 shs
The 7 Hottest IPO Stories of 2026 Cover
The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Can-Fite BioPharma Ltd. stock logo
CANF
Can-Fite BioPharma
+3.02%+1.15%-22.01%-53.12%-79.65%
CNS Pharmaceuticals, Inc. stock logo
CNSP
CNS Pharmaceuticals
-4.62%-3.77%-18.11%-15.81%-34.24%
Enveric Biosciences, Inc. stock logo
ENVB
Enveric Biosciences
-2.67%-0.68%-3.31%-6.41%-74.39%
Scienture Holdings, Inc. stock logo
SCNX
Scienture
-0.87%+0.59%-7.82%-63.29%-83.28%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Can-Fite BioPharma Ltd. stock logo
CANF
Can-Fite BioPharma
$1.67
+3.0%		$2.16
$1.50
▼
$12.30
$1.79M1.16880,380 shs14,117 shs
CNS Pharmaceuticals, Inc. stock logo
CNSP
CNS Pharmaceuticals
$4.34
-4.6%		$5.24
$1.90
▼
$10.54
$6.65M3.2116,535 shs4,019 shs
Enveric Biosciences, Inc. stock logo
ENVB
Enveric Biosciences
$1.46
-2.7%		$1.46
$1.17
▼
$13.25
$6.71M1.2350,913 shs35,765 shs
Scienture Holdings, Inc. stock logo
SCNX
Scienture
$3.42
-0.9%		$5.88
$2.64
▼
$21.50
$6.09M3.5762,318 shs14,100 shs
The 7 Hottest IPO Stories of 2026 Cover
The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Can-Fite BioPharma Ltd. stock logo
CANF
Can-Fite BioPharma
+3.02%+1.15%-22.01%-53.12%-79.65%
CNS Pharmaceuticals, Inc. stock logo
CNSP
CNS Pharmaceuticals
-4.62%-3.77%-18.11%-15.81%-34.24%
Enveric Biosciences, Inc. stock logo
ENVB
Enveric Biosciences
-2.67%-0.68%-3.31%-6.41%-74.39%
Scienture Holdings, Inc. stock logo
SCNX
Scienture
-0.87%+0.59%-7.82%-63.29%-83.28%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Can-Fite BioPharma Ltd. stock logo
CANF
Can-Fite BioPharma
2.67
Moderate Buy$44.002,536.31% Upside
CNS Pharmaceuticals, Inc. stock logo
CNSP
CNS Pharmaceuticals
1.00
SellN/AN/A
Enveric Biosciences, Inc. stock logo
ENVB
Enveric Biosciences
1.00
SellN/AN/A
Scienture Holdings, Inc. stock logo
SCNX
Scienture
2.00
Hold$6.0075.44% Upside

Current Analyst Ratings Breakdown

Latest CANF, CNSP, ENVB, and SCNX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
10/23/2026
Scienture Holdings, Inc. stock logo
SCNX
Scienture
Maxim Group logo
Maxim Group
Subscribe to MarketBeat All Access to unlock brokerage rankings
Set Price TargetBuy$37.50 ➝ $6.00
10/15/2026
CNS Pharmaceuticals, Inc. stock logo
CNSP
CNS Pharmaceuticals
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingSell (E+)
10/15/2026
Enveric Biosciences, Inc. stock logo
ENVB
Enveric Biosciences
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingSell (E+)
10/2/2026
Scienture Holdings, Inc. stock logo
SCNX
Scienture
Zacks Research logo
Zacks Research
Subscribe to MarketBeat All Access to unlock brokerage rankings
UpgradeHold
9/29/2026
Can-Fite BioPharma Ltd. stock logo
CANF
Can-Fite BioPharma
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingBuy
9/21/2026
Scienture Holdings, Inc. stock logo
SCNX
Scienture
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingSell (E+)
(Data available from 11/5/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Can-Fite BioPharma Ltd. stock logo
CANF
Can-Fite BioPharma
$405K4.41N/AN/A$1.76 per share0.95
CNS Pharmaceuticals, Inc. stock logo
CNSP
CNS Pharmaceuticals
N/AN/AN/AN/A$7.29 per shareN/A
Enveric Biosciences, Inc. stock logo
ENVB
Enveric Biosciences
N/AN/AN/AN/A$7.00 per shareN/A
Scienture Holdings, Inc. stock logo
SCNX
Scienture
$430K14.00N/AN/A$43.15 per share0.08
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Can-Fite BioPharma Ltd. stock logo
CANF
Can-Fite BioPharma
-$7.63M-$14.80N/AN/AN/AN/AN/AN/AN/A
CNS Pharmaceuticals, Inc. stock logo
CNSP
CNS Pharmaceuticals
-$15.85M-$23.59N/AN/AN/AN/A-204.25%-141.87%11/18/2026 (Estimated)
Enveric Biosciences, Inc. stock logo
ENVB
Enveric Biosciences
-$8.77M-$12.65N/AN/AN/AN/A-168.04%-145.95%11/12/2026 (Estimated)
Scienture Holdings, Inc. stock logo
SCNX
Scienture
-$41.51M-$52.50N/AN/AN/AN/A-53.51%-42.47%11/11/2026 (Estimated)

Latest CANF, CNSP, ENVB, and SCNX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/18/2026Q3 2026
CNS Pharmaceuticals, Inc. stock logo
CNSP
CNS Pharmaceuticals
-$0.27N/AN/AN/AN/AN/A
11/11/2026Q3 2026
Scienture Holdings, Inc. stock logo
SCNX
Scienture
-$1.57N/AN/AN/A$1.22 millionN/A
8/14/2026Q2 2026
Enveric Biosciences, Inc. stock logo
ENVB
Enveric Biosciences
N/A-$0.76N/A-$0.76N/AN/A
8/13/2026Q2 2026
Scienture Holdings, Inc. stock logo
SCNX
Scienture
-$2.25-$0.07+$2.18-$1.75$1.96 million$0.34 million
8/12/2026Q2 2026
CNS Pharmaceuticals, Inc. stock logo
CNSP
CNS Pharmaceuticals
-$0.24-$0.38-$0.14-$0.38N/AN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Can-Fite BioPharma Ltd. stock logo
CANF
Can-Fite BioPharma
N/AN/AN/AN/AN/A
CNS Pharmaceuticals, Inc. stock logo
CNSP
CNS Pharmaceuticals
N/AN/AN/AN/AN/A
Enveric Biosciences, Inc. stock logo
ENVB
Enveric Biosciences
N/AN/AN/AN/AN/A
Scienture Holdings, Inc. stock logo
SCNX
Scienture
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Can-Fite BioPharma Ltd. stock logo
CANF
Can-Fite BioPharma
N/A
2.93
N/A
CNS Pharmaceuticals, Inc. stock logo
CNSP
CNS Pharmaceuticals
N/A
5.86
5.86
Enveric Biosciences, Inc. stock logo
ENVB
Enveric Biosciences
N/A
10.21
10.21
Scienture Holdings, Inc. stock logo
SCNX
Scienture
0.15
3.04
2.97

Institutional Ownership

CompanyInstitutional Ownership
Can-Fite BioPharma Ltd. stock logo
CANF
Can-Fite BioPharma
21.00%
CNS Pharmaceuticals, Inc. stock logo
CNSP
CNS Pharmaceuticals
14.02%
Enveric Biosciences, Inc. stock logo
ENVB
Enveric Biosciences
13.82%
Scienture Holdings, Inc. stock logo
SCNX
Scienture
5.68%

Insider Ownership

CompanyInsider Ownership
Can-Fite BioPharma Ltd. stock logo
CANF
Can-Fite BioPharma
0.80%
CNS Pharmaceuticals, Inc. stock logo
CNSP
CNS Pharmaceuticals
1.82%
Enveric Biosciences, Inc. stock logo
ENVB
Enveric Biosciences
2.41%
Scienture Holdings, Inc. stock logo
SCNX
Scienture
19.51%
CompanyEmployeesShares OutstandingFree FloatOptionable
Can-Fite BioPharma Ltd. stock logo
CANF
Can-Fite BioPharma
51.07 millionN/ANot Optionable
CNS Pharmaceuticals, Inc. stock logo
CNSP
CNS Pharmaceuticals
81.46 million1.43 millionNot Optionable
Enveric Biosciences, Inc. stock logo
ENVB
Enveric Biosciences
64.48 million4.37 millionNot Optionable
Scienture Holdings, Inc. stock logo
SCNX
Scienture
91.76 million1.42 millionN/A

Recent News About These Companies

Scienture Stock Earnings Estimates Decreased by Maxim Group
 |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31178680
Scienture Holdings Consensus Price Target Lowered by 84% to $6.12
November 2 at 6:57 PM  |  msn.comhttps://www.msn.com/en-us/science/statistics/scienture-holdings-consensus-price-target-lowered-by-84-to-6-12/ar-AA2gAQwo
Scienture Holdings, Inc. (SCNX) Shareholder/Analyst Call Prepared Remarks Transcript
October 28, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4958825-scienture-holdings-inc-scnx-shareholder-analyst-call-prepared-remarks-transcript
Scienture Holdings Consensus Price Target Increased by 2,400% to $38.25
October 23, 2026  |  msn.comhttps://www.msn.com/en-us/money/top-stocks/scienture-holdings-consensus-price-target-increased-by-2-400-to-38-25/ar-AA2fUbHC
SCIENTURE Issues Shareholder Letter Highlighting Sequential Revenue Growth, Two FDA-Approved Commercial Products, and Continued Progress Toward Profitability in 2027
October 22, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/scienture-issues-shareholder-letter-highlighting-sequential-revenue-growth-two-fda-approved-commercial-products-and-continued-progress-toward-profitability-in-2027-1036654390
SCIENTURE Issues Shareholder Letter Highlighting Sequential Revenue Growth, Two FDA-Approved Commercial Products, and Continued Progress Toward Profitability in 2027
October 22, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/10/22/3386312/0/en/scienture-issues-shareholder-letter-highlighting-sequential-revenue-growth-two-fda-approved-commercial-products-and-continued-progress-toward-profitability-in-2027.html
Scienture Holdings Regains Nasdaq Compliance Amid Revenue Surge
October 19, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/scienture-holdings-regains-nasdaq-compliance-amid-revenue-surge?utm_source=marketbeat.com&utm_medium=referral
Scienture Reports Preliminary Q3 Revenue of $1.22 Million, Up 256%
October 19, 2026  |  quiverquant.comQ
SCIENTURE Reports Approximately $1.22 Million in Unaudited Preliminary Q3 2026 Revenue, Achieving 256% Sequential Growth
October 13, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/10/13/3379660/0/en/scienture-reports-approximately-1-22-million-in-unaudited-preliminary-q3-2026-revenue-achieving-256-sequential-growth.html
SCIENTURE Announces Arbli Added to Formularies at Three Leading U.S. Pediatric Academic Medical Centers and Hospitals
October 5, 2026  |  marketscreener.comM
Exclusive: Scienture expands institutional reach for hypertension drug with new hospital adoptions
October 2, 2026  |  msn.comhttps://www.msn.com/en-us/news/other/exclusive-scienture-expands-institutional-reach-for-hypertension-drug-with-new-hospital-adoptions/ar-AA2dpL8b
SCIENTURE Announces Arbli™ Added to Formularies at Three Leading U.S. Pediatric Academic Medical Centers and Hospitals
October 2, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/10/02/3373784/0/en/scienture-announces-arbli-added-to-formularies-at-three-leading-u-s-pediatric-academic-medical-centers-and-hospitals.html
Scienture announces 1-for-25 reverse stock split
September 30, 2026  |  msn.comhttps://www.msn.com/en-us/news/other/scienture-announces-1-for-25-reverse-stock-split/ar-AA2dipMx
Scienture Holdings, Inc. Announces Reverse Stock Split
September 30, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/30/3372380/0/en/scienture-holdings-inc-announces-reverse-stock-split.html
Scienture Expands REZENOPY Reach To Addiction Centers Under Distribution Deal
September 22, 2026  |  rttnews.comhttps://www.rttnews.com/3692951/scienture-expands-rezenopy-reach-to-addiction-centers-under-distribution-deal.aspx
Scienture signs deal to sell Rezenopy at 2,000 addiction clinics
September 22, 2026  |  streetinsider.comhttps://www.streetinsider.com/Corporate+News/Scienture+signs+deal+to+sell+Rezenopy+at+2%2C000+addiction+clinics/27088065.html
SCIENTURE Expands Commercial Reach of REZENOPY™ to Addiction Treatment Centers through an Agreement with a Distribution Partner
September 22, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/22/3366320/0/en/scienture-expands-commercial-reach-of-rezenopy-to-addiction-treatment-centers-through-an-agreement-with-a-distribution-partner.html
SCIENTURE to Present at the H.C. Wainwright 28th Annual Global Investment Conference on September 14, 2026
September 9, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/09/3358685/0/en/scienture-to-present-at-the-h-c-wainwright-28th-annual-global-investment-conference-on-september-14-2026.html
Scienture Holdings Reports Q2 2026 Results, Launches REZENOPY™ and Narrows Losses
August 14, 2026  |  quiverquant.comQ
SCIENTURE Reports Q2 2026 Results with Approximately 510% Sequential Revenue Growth from Q1 2026 and Significant Improvement in Operating Performance
August 14, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/08/14/3345299/0/en/scienture-reports-q2-2026-results-with-approximately-510-sequential-revenue-growth-from-q1-2026-and-significant-improvement-in-operating-performance.html

New MarketBeat Followers Over Time

Media Sentiment Over Time

Can-Fite BioPharma stock logo

Can-Fite BioPharma NYSE:CANF

$1.67 +0.05 (+3.02%)
Closing price 11/4/2026 03:59 PM Eastern
Extended Trading
$1.67 0.00 (-0.18%)
As of 04:58 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19. It also develops Namodenoson that is in Phase III clinical trial for the treatment of hepatocellular carcinoma, as well as in Phase IIb trial for the treatment of non-alcoholic steatohepatitis; and CF602, which is in pre-clinical trial for the treatment of erectile dysfunction. In addition, the company develops commercial predictive biomarker blood test kit for A3AR. Can-Fite BioPharma Ltd. has license and collaboration agreement with CMS Medical to develop, manufacture, and commercialize Piclidenoson and Namodenoson; and collaboration agreement with Univo Pharmaceuticals to identify and co-develop specific formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. The company was formerly known as Can-Fite Technologies Ltd. and changed its name to Can-Fite BioPharma Ltd. in January 2001. Can-Fite BioPharma Ltd. was incorporated in 1994 and is headquartered in Petah Tikva, Israel.

CNS Pharmaceuticals stock logo

CNS Pharmaceuticals NASDAQ:CNSP

$4.34 -0.21 (-4.62%)
Closing price 11/4/2026 03:51 PM Eastern
Extended Trading
$4.30 -0.04 (-0.92%)
As of 04:02 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company's lead drug candidate is Berubicin, which completed Phase I clinical trial that is used for the treatment of glioblastoma multiforme. It has license agreements with Houston Pharmaceuticals, Inc., Reata Pharmaceuticals, Inc., Pomeranian Medical University, and The University of Texas M.D. Anderson Cancer Center; and a development agreement with WPD Pharmaceuticals Inc. The company was incorporated in 2017 and is based in Houston, Texas.

Enveric Biosciences stock logo

Enveric Biosciences NASDAQ:ENVB

$1.46 -0.04 (-2.67%)
Closing price 11/4/2026 03:59 PM Eastern
Extended Trading
$1.46 +0.00 (+0.07%)
As of 04:00 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Enveric Biosciences, Inc., a biotechnology company, engages in the development of small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders. Its lead product candidates are EB-002, an active metabolite of psilocybin, which is in preclinical development stage for the treatment of anxiety disorders; and EB-003 that is in preclinical development stage for the treatment mental health. The company also focuses on the development of cannabinoid conjugate molecules for the treatment of pain and cancer. Enveric Biosciences, Inc. is headquartered in Naples, Florida.

Scienture stock logo

Scienture NASDAQ:SCNX

$3.42 -0.03 (-0.87%)
Closing price 11/4/2026 04:00 PM Eastern
Extended Trading
$3.32 -0.11 (-3.07%)
As of 05:03 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Scienture Holdings, Inc. engages in the provision of health services and pharmaceutical products. It focuses on addressing underserved patients and indications through novel product concepts and innovation. The company was founded on July 15, 2005 and is headquartered in Lutz, FL.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas